248 related articles for article (PubMed ID: 34363021)
1. ITLN1 inhibits tumor neovascularization and myeloid derived suppressor cells accumulation in colorectal carcinoma.
Chen L; Jin XH; Luo J; Duan JL; Cai MY; Chen JW; Feng ZH; Guo AM; Wang FW; Xie D
Oncogene; 2021 Oct; 40(40):5925-5937. PubMed ID: 34363021
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of intelectin-1 in colorectal cancer: Intelectin-1 participates in tumor suppression and favorable progress.
Katsuya N; Sentani K; Sekino Y; Yamamoto Y; Kobayashi G; Babasaki T; Oue N; Amatya VJ; Takeshima Y; Yasui W
Pathol Int; 2020 Dec; 70(12):943-952. PubMed ID: 33002285
[TBL] [Abstract][Full Text] [Related]
3. Intelectin 1 suppresses tumor progression and is associated with improved survival in gastric cancer.
Li D; Zhao X; Xiao Y; Mei H; Pu J; Xiang X; Jiao W; Song H; Qu H; Huang K; Zheng L; Tong Q
Oncotarget; 2015 Jun; 6(18):16168-82. PubMed ID: 25965823
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of the premetastatic niche facilitating colorectal cancer liver metastasis generated from myeloid-derived suppressor cells induced by the S1PR1-STAT3 signaling pathway.
Lin Q; Ren L; Jian M; Xu P; Li J; Zheng P; Feng Q; Yang L; Ji M; Wei Y; Xu J
Cell Death Dis; 2019 Sep; 10(10):693. PubMed ID: 31534132
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer.
Sasidharan Nair V; Saleh R; Toor SM; Taha RZ; Ahmed AA; Kurer MA; Murshed K; Alajez NM; Abu Nada M; Elkord E
Clin Epigenetics; 2020 Jan; 12(1):13. PubMed ID: 31941522
[TBL] [Abstract][Full Text] [Related]
6. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
7. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
Wang L; Hu D; Xie B; Xie L
Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
[TBL] [Abstract][Full Text] [Related]
8. Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer.
Yang R; Cai TT; Wu XJ; Liu YN; He J; Zhang XS; Ma G; Li J
Immunology; 2018 Oct; 155(2):263-272. PubMed ID: 29770434
[TBL] [Abstract][Full Text] [Related]
9. Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2.
Li D; Mei H; Pu J; Xiang X; Zhao X; Qu H; Huang K; Zheng L; Tong Q
Mol Cancer; 2015 Feb; 14():47. PubMed ID: 25889839
[TBL] [Abstract][Full Text] [Related]
10. Intelectin1 ameliorates macrophage activation via inhibiting the nuclear factor kappa B pathway.
Kobayashi H; Uchimura K; Ishii T; Takahashi K; Mori K; Tsuchiya K; Furuya F
Endocr J; 2022 May; 69(5):539-546. PubMed ID: 34866068
[TBL] [Abstract][Full Text] [Related]
11. Chronic restraint stress promotes the mobilization and recruitment of myeloid-derived suppressor cells through β-adrenergic-activated CXCL5-CXCR2-Erk signaling cascades.
Cao M; Huang W; Chen Y; Li G; Liu N; Wu Y; Wang G; Li Q; Kong D; Xue T; Yang N; Liu Y
Int J Cancer; 2021 Jul; 149(2):460-472. PubMed ID: 33751565
[TBL] [Abstract][Full Text] [Related]
12. S100A9 Regulates MDSCs-Mediated Immune Suppression via the RAGE and TLR4 Signaling Pathways in Colorectal Carcinoma.
Huang M; Wu R; Chen L; Peng Q; Li S; Zhang Y; Zhou L; Duan L
Front Immunol; 2019; 10():2243. PubMed ID: 31620141
[TBL] [Abstract][Full Text] [Related]
13. The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury.
Zhang C; Wang S; Li J; Zhang W; Zheng L; Yang C; Zhu T; Rong R
Cell Death Dis; 2017 Mar; 8(3):e2695. PubMed ID: 28333137
[TBL] [Abstract][Full Text] [Related]
14. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
[TBL] [Abstract][Full Text] [Related]
15. TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer.
Gneo L; Rizkalla N; Hejmadi R; Mussai F; de Santo C; Middleton G
Cancer Immunol Immunother; 2022 Jul; 71(7):1583-1596. PubMed ID: 34727230
[TBL] [Abstract][Full Text] [Related]
16. Gansui-Banxia Decoction extraction inhibits MDSCs accumulation via AKT /STAT3/ERK signaling pathways to regulate antitumor immunity in C57bl/6 mice.
Feng XY; Chen BC; Li JC; Li JM; Li HM; Chen XQ; Liu D; Li RT
Phytomedicine; 2021 Dec; 93():153779. PubMed ID: 34638030
[TBL] [Abstract][Full Text] [Related]
17. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells accumulate among myeloid cells contributing to tumor growth in matrix metalloproteinase 12 knockout mice.
Li J; Zhang X; Liu Q; Yang M; Zhou Z; Ye Y; Zhou Z; He X; Wang L
Cell Immunol; 2018 May; 327():1-12. PubMed ID: 29555056
[TBL] [Abstract][Full Text] [Related]
19. Mannan-Binding Lectin Deficiency Limits Inflammation-induced Myeloid-Derived Suppressor Cells Expansion via Modulating Tumor Necrosis Factor Alpha-triggered Apoptosis.
Dong L; Jiang H; Chen K; Xie J; An Q; Deng F; Sun Z; Liu Y; Zhou J; Zhang L; Lu X; Wang M; Chen Z; Zou X; Zuo D
Int J Biol Sci; 2022; 18(4):1580-1593. PubMed ID: 35280697
[No Abstract] [Full Text] [Related]
20. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.
Binsfeld M; Muller J; Lamour V; De Veirman K; De Raeve H; Bellahcène A; Van Valckenborgh E; Baron F; Beguin Y; Caers J; Heusschen R
Oncotarget; 2016 Jun; 7(25):37931-37943. PubMed ID: 27177328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
